Levobupivacaine Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine is a local anesthetic that provides regional nerve block for several procedural settings.

• Surgical anesthesia: enables intra‑operative analgesia and muscle relaxation during operative procedures.
• Post‑operative analgesia: extends pain relief after surgery to reduce opioid requirement.
• Labor analgesia: offers effective pain reduction during childbirth while preserving maternal consciousness.

• Levobupivacaine reversibly blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. By stabilising the neuronal membrane, it inhibits nerve impulse transmission in the targeted region, resulting in loss of sensation and analgesia without affecting consciousness.

Levobupivacaine may cause a range of adverse reactions, most of which are related to its local anesthetic properties.

Common Side Effects

• Injection site pain: discomfort at the site of administration.
• Transient numbness: temporary loss of sensation in the blocked area.
• Lightheadedness: mild dizziness during or after the procedure.
• Nausea: occasional upset stomach.
• Blurred vision: temporary visual disturbances.

Serious or Rare Side Effects

• Cardiovascular toxicity: arrhythmias or hypotension in high systemic exposure.
• Central nervous system toxicity: seizures or altered mental status.
• Allergic reaction: rash, itching, or anaphylaxis.
• Persistent motor block: prolonged weakness beyond expected duration.
• Methemoglobinemia: rare blood disorder causing reduced oxygen delivery.

When using Levobupivacaine, clinicians should consider patient‑specific factors and procedural requirements.

• Cardiac assessment: monitor patients with known heart disease for arrhythmias.
• Dose calculation: ensure total dose does not exceed recommended maximum for the specific route.
• Neurological monitoring: observe for signs of prolonged motor or sensory block.
• Drug interactions: avoid concurrent use with other potent local anesthetics.
• Pregnancy and lactation: evaluate risk‑benefit ratio before use in pregnant or breastfeeding patients.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Levobupivacaine can interact with other agents that affect the cardiovascular or central nervous systems.

Major Interactions (Avoid)

• Class I anti‑arrhythmic drugs: may potentiate cardiotoxic effects.
• Other local anesthetics: increase risk of systemic toxicity.
• Beta‑blockers: can exacerbate bradycardia when combined.

Moderate Interactions (Monitor Closely)

• CNS depressants (e.g., benzodiazepines): may enhance sedation.
• Calcium channel blockers: may affect cardiac conduction.
• MAO inhibitors: potential for increased neurotoxicity.